Air cargo volumes of pharmaceutical products moving between Europe and Brazil expanded 150% during 2026, according to Air Cargo Week, raising fresh questions about which carriers, airports, and cold-chain handlers are absorbing the surge.

The trade publication surfaced the figure this week without disclosing its underlying tally — whether carrier filings, customs records, handler tonnage, or a market-intelligence estimate. The 150% growth translates to a 2.5x expansion relative to the lane's prior base, an unusually large intercontinental move for a freight category generally measured in low double-digit annual change.

What product mix is driving the increase?

The summary does not break the increase down by therapeutic class, temperature band, or country of origin. Pharmaceutical air freight typically covers vaccines, biologics, biosimilars, clinical-trial materials, and high-value active pharmaceutical ingredients — categories that move under IATA's Time and Temperature Sensitive Products framework and, increasingly, under the CEIV-Phora certification regime for participating carriers and handlers.

Brazil imports the majority of its high-value pharmaceutical inputs, with European biologics producers supplying a growing share. The demand profile has tracked an aging population, expanding private health-insurance coverage, and a public-sector push to localise vaccine production that has not yet closed the import gap on higher-margin biologics.

Which corridors and gateways handle the freight?

The headline does not name forwarders, combination carriers, integrators, or freighters. Latin American combination carriers are plausible operators on routes out of Brazil's principal gateways, with São Paulo's Guarulhos handling the bulk of European-bound pharmaceutical freight and Viracopos, near Campinas, serving as a secondary air-cargo node. European origin tonnage typically clusters at Frankfurt, Brussels, and Amsterdam Schiphol — three stations with established temperature-controlled handling capacity.

Without a carrier-level disclosure, the split between scheduled passenger-belly cargo and dedicated freighters remains unknown. That split matters, because CEIV-Phora operating standards impose handling requirements that vary by aircraft type and by the level of ground-station investment.

Is the corridor's cold chain keeping pace?

A sustained rise in pharmaceutical tonnage tests three pressure points: the origin warehouse's refrigerated acceptance, the aircraft hold's temperature envelope, and the destination handler's apron-to-truck chain. Brazilian stations have invested in cooler apron infrastructure at the principal gateways in recent years, where multiple ground handlers operate refrigerated acceptance and customs-cleared cool-chain storage.

Whether those investments absorbed a 2.5x volume increase without service degradation is a question the source does not address. Service quality on the lane surfaces in complaint filings with Brazilian health regulators and in rejected-product claims from importers, neither of which Air Cargo Week cites.

What remains unverified

The 150% figure rests on a single trade publication summary. Air Cargo Week did not disclose its methodology, the data period the percentage covers, or whether the increase applies to tonnage, number of shipments, or revenue tonne kilometres. Industry readers should treat the headline as a directional signal pending corroboration from carriers, integrators, or Brazilian customs returns.

A figure of this magnitude, if sustained, would reshape routing economics on the Europe-Brazil lane and feed directly into next year's capacity-planning cycles for carriers, handlers, and forwarders on both sides of the Atlantic.